Allarity Therapeutics

ALLR · NASDAQ

$0.8758+$0.0028 (+0.32%)TodayMarket closed · Oct 20, 7:12 PM ET

Prev close $0.873

ALLR analyst rating

BuyConsensus of 1 analyst over the last 12 months. 100% rate it a buy.

Strong buy0
Buy1
Hold0
Underperform0
Sell0

12-month price target · 3 analysts

Average $11.22 (+1181.1% upside)

Low: $11.11
Now: $0.8758
High: $11.55

Upgrades and downgrades

The latest rating actions, newest first

ALLR analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Ascendiant Capital	Sep 16, 2026	Maintains	Buy	$10.25 → $11.00	28%
Ascendiant Capital	Jun 8, 2026	Maintains	Buy	$9.75 → $10.25	28%
Ascendiant Capital	Apr 10, 2026	Maintains	Buy	$9.50 → $9.75	28%
Ascendiant Capital	Dec 9, 2025	Maintains	Buy	$9.25 → $9.50	28%

The case for and against

Updated Oct 14, 2026

Bull case

Allarity Therapeutics is compelling because its proprietary Drug Response Predictor platform supports a precision-medicine strategy that may improve patient selection and amplify Stenoparib’s clinical benefit in advanced ovarian cancer. The lead program is already in a Phase 2 trial and has shown encouraging durability, including median overall survival exceeding 25 months and two patients remaining on treatment for more than 29 months as of March 2026, while a second Phase 2 SCLC study began enrolling in February 2026. Fundamentally, the bullish view is also supported by an attractive valuation backdrop versus the ~$9.0 billion PARP inhibitor market in 2023, with sales forecast to exceed $21.0 billion by 2031, and 2026 EPS estimated at $(0.80).

Bear case

Allarity Therapeutics is a clinical-stage company with essentially no revenue, reporting about $0 million in both fiscal Q1 2026 and Q2 2026, while net losses widened to $2.8 million and $3.4 million, respectively, underscoring the lack of operating leverage. Its investment case remains burdened by balance sheet and liquidity risk, and the absence of guidance or meaningful commercial traction highlights continued dependence on external financing. The outlook is negative because stenoparib still faces long development challenges and major binary risks around clinical safety and efficacy, regulatory approval, reimbursement, and eventual commercialization.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.